Annual Total Long Term Liabilities
$304.67 M
+$45.09 M+17.37%
31 December 2023
Summary:
ArriVent BioPharma Common Stock annual total long term liabilities is currently $304.67 million, with the most recent change of +$45.09 million (+17.37%) on 31 December 2023. During the last 3 years, it has risen by +$304.67 million (+100.00%). AVBP annual total long term liabilities is now at all-time high.AVBP Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$304.67 M
+$304.57 M+310784.69%
01 September 2024
Summary:
ArriVent BioPharma Common Stock quarterly total long term liabilities is currently $304.67 million, with the most recent change of +$304.57 million (+310784.69%) on 01 September 2024. Over the past year, it has stayed the same.AVBP quarterly long term liabilities is now at all-time high.AVBP Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVBP Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | 0.0% |
| 3 y3 years | +100.0% | - |
| 5 y5 years | - | - |
AVBP Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | at high | ||
| 5 y | 5 years | at high | at high | ||
| alltime | all time | at high | at high |
ArriVent BioPharma Common Stock Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $304.67 M(>+9900.0%) |
| June 2024 | - | $98.00 K(-29.0%) |
| Mar 2024 | - | $138.00 K(-100.0%) |
| Dec 2023 | $304.67 M | $304.67 M(+0.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $304.49 M(>+9900.0%) |
| June 2023 | - | $0.00(-100.0%) |
| Dec 2022 | $259.58 M(>+9900.0%) | - |
| Dec 2022 | - | $259.58 M |
| Dec 2021 | $0.00 | - |
FAQ
- What is ArriVent BioPharma Common Stock annual total long term liabilities?
- What is the all time high annual total long term liabilities for ArriVent BioPharma Common Stock?
- What is ArriVent BioPharma Common Stock quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for ArriVent BioPharma Common Stock?
- What is ArriVent BioPharma Common Stock quarterly long term liabilities year-on-year change?
What is ArriVent BioPharma Common Stock annual total long term liabilities?
The current annual total long term liabilities of AVBP is $304.67 M
What is the all time high annual total long term liabilities for ArriVent BioPharma Common Stock?
ArriVent BioPharma Common Stock all-time high annual total long term liabilities is $304.67 M
What is ArriVent BioPharma Common Stock quarterly total long term liabilities?
The current quarterly long term liabilities of AVBP is $304.67 M
What is the all time high quarterly long term liabilities for ArriVent BioPharma Common Stock?
ArriVent BioPharma Common Stock all-time high quarterly total long term liabilities is $304.67 M
What is ArriVent BioPharma Common Stock quarterly long term liabilities year-on-year change?
Over the past year, AVBP quarterly total long term liabilities has changed by $0.00 (0.00%)